CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology
company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman,
President, and Chief Executive Officer, will present a corporate overview at the Barclays Global Healthcare Conference, being held
in Miami on March 13-15, 2018.
2018 Barclays Global Healthcare Conference – Leap Presentation Details:
Date: Wednesday, March 14, 2018
Time: 2:05 P.M.
The presentation will be webcast live and may be accessed on the Investors page of the company’s website at
www.investors.leaptx.com, where a replay of the event will also be available for a limited
time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq:LPTX) is developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate,
DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical
trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients
with defined mutations of the Wnt pathway and in combinations with immune checkpoint inhibitors. Leap’s second clinical candidate,
TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response that is
in two advanced solid tumor studies. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements include statements relating to Leap’s expectations with respect to the development and
advancement of DKN-01, TRX518, and other programs, including the initiation, timing and design of future studies, enrollment in
future studies, business development, and other future expectations, plans and prospects. Leap has attempted to identify forward
looking statements by such terminology as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘projects,’’
‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Although Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made, forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not
limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the
ability to complete a financing or form business development relationships to fund our expenses; the outcome, cost, and timing of
our product development activities and clinical trials; the uncertain clinical development process, including the risk that
clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our plans to research, develop, and commercialize our drug product candidates; our ability
to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and
commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the
markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our
drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially
will be included in Leap Therapeutics’ periodic filings with the Securities and Exchange Commission (the "SEC"),
including Leap Therapeutics’ Form 10-K that Leap filed with the SEC on February 23, 2018. These statements are only predictions and
involve known and unknown risks, uncertainties, and other factors. Any forward looking statements contained in this release speak
only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Susan Kim
212-203-4433
susan@argotpartners.com
or
Heather Savelle
617-663-4863
heather@argotpartners.com